Among the notable presentations, Dr. Frank Sinicrope will discuss a study on circulating tumor DNA assays in colorectal cancer treatment on May 30, followed by a plenary session on June 1 focusing on a randomized trial combining chemotherapy with atezolizumab for stage 3 deficient DNA mismatch repair colon cancer.

Additionally, Dr. Thorvardur Halfdanarson will present findings on the toxicity of [212Pb]VMT-α-NET therapy for neuroendocrine tumors during an oral session on May 30.

Research on solid tumors will explore disparities in gastric cancer, machine learning applications for breast cancer metastasis, and promising antibody-drug conjugates for lung cancer, highlighting the impact of innovative approaches in oncology.

Key research areas at the conference will also include studies on chemotherapy methods, artificial intelligence in oncology, home cancer care, and new treatments for breast cancer and melanoma.

An important Clinical Science Symposium on May 31 will address the HemOnc workforce's perceptions of artificial intelligence in clinical practice, led by Dr. Guilherme Sacchi de Camargo Correia.

On June 1, Dr. Roxana Dronca will lead a poster session discussing trials comparing home-based versus in-clinic cancer therapy administration, showcasing the Cancer Care Beyond Walls initiative.

Dr. Andre Goy will emphasize the importance of ongoing research for cancers that do not respond to standard treatments, underscoring the commitment to advancing oncology through innovative therapies.

Three Hematology/Oncology Fellows from Roswell Park, Yu Fujiwara, Zunairah Shah, and Vinit Singh, will be recognized with ASCO Annual Meeting Merit Awards for their significant research contributions.

Dr. David Routman will present initial results from a trial investigating a therapeutic vaccine for HPV-associated oropharyngeal carcinoma on June 2, showcasing advancements in cancer immunotherapy.

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, will feature significant research presentations from major cancer centers, including Hackensack Meridian John Theurer Cancer Center, Mayo Clinic, and Roswell Park Comprehensive Cancer Center.

Highlighted findings will cover novel drug combinations for multiple myeloma, racial disparities in treatment outcomes, and biomarkers for disease relapse in leukemia and lymphoma.